Akebia Therapeutics, INC 8-K filings

Akebia Therapeutics announced its fourth quarter and full year 2023 financial results, highlighted by Auryxia revenue within guidance and preparations for a potential vadadustat launch, pending FDA approval.

Akebia Therapeutics has further extended the separation dates for its Chief Operating Officer and Senior Vice President, Chief Legal Officer and Secretary.

Akebia Therapeutics has entered into a new $55 million term loan facility with Kreos Capital, which includes an initial $37 million tranche and the refinancing of its previous debt with Pharmakon.